View this Resource & FAQ page for training, current research, use protocols, and device FAQs.
The Subsalve Oxygen Treatment Hood is the critical patient interface to enable Hooded/Helmet Positive Airway Pressure (HPAP) ventilation techniques, and was developed in response to the Covid-19 pandemic.
HPAP is also referred to as non-invasive positive pressure ventilation (NIPPV), helmet NIV, helmet CPAP, or simply helmet based ventilation.
HPAP ventilation techniques allow clinicians to:
The Subsalve Oxygen Treatment Hood is the only such US manufactured device with FDA Emergency Use Authorization (EUA) for respiratory distress and is being distributed within the US and internationally.
The project has been supported by multiple partners, and has resulted in the provision of humanitarian aid to numerous countries including Bolivia, Honduras, Guatemala, Nicaragua, Mexico, Haiti, Nigeria, Indonesia, Iraq, and others.
Among patients with ARDS, treatment with helmet [hood] NIV resulted in a significant reduction of intubation rates.
…the helmets that your company [Subsalve] produces are fantastic and already saved and continue saving lives in Bolivia. Our physicians are more familiar and eager to use the device and share the benefits with other hospitals.
Approximately 30–50% of patients were successfully managed with helmet respiratory support, not requiring escalation to intubation and mechanical ventilation.
Effective August 4th, 2020, the US FDA has authorized the Subsalve Oxygen Treatment Hood for emergency use in healthcare settings to treat patients during the COVID-19 pandemic, and has been added to Appendix B of the FDA’s Emergency Use Authorization (EUA).
The Subsalve Oxygen Treatment Hood is a patient interface intended for helmet based Non Invasive Positive Pressure Ventilation (NIPPV) according to clinician established protocols.